Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

0.8968
+0.08149.98%
Post-market: 0.93000.0332+3.70%19:58 EDT
Volume:2.54M
Turnover:2.27M
Market Cap:165.42M
PE:-1.07
High:0.9500
Open:0.8998
Low:0.8421
Close:0.8154
Loading ...

Nektar Therapeutics' (NASDAQ:NKTR) latest 18% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.
·
09 Feb

Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a Turnaround

Zacks
·
07 Feb

Nektar Names Kotzin Interim Chief Medical Officer

Dow Jones
·
05 Feb

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

Zacks
·
03 Feb

Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks
·
31 Jan

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Zacks
·
31 Jan

MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?

Zacks
·
27 Jan

Analysts Are Bullish on These Healthcare Stocks: Monopar Therapeutics Inc (MNPR), Nektar Therapeutics (NKTR)

TIPRANKS
·
22 Jan

Nektar Therapeutics Price Target Maintained With a $6.50/Share by HC Wainwright & Co.

Dow Jones
·
13 Jan

Nektar Therapeutics: Promising Drug Pipeline and Strategic Expansion Drive Buy Rating

TIPRANKS
·
13 Jan

Buy Rating for Nektar Therapeutics: Promising Clinical Trial Strategy and Efficacy of Rezpeg

TIPRANKS
·
11 Jan

BRIEF-Nektar Therapeutics Announces Completion Of Target Enrollment In Rezolve-Ad Phase 2B Clinical Trial Of Rezpegaldesleukin In Patients With Moderate-To-Severe Atopic Dermatitis

Reuters
·
10 Jan

Nektar completes enrollment in REZOLVE-AD Phase 2b study of rezpegaldesleukin

TIPRANKS
·
10 Jan

Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Ad Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Moderate-to-Severe Atopic Dermatitis

THOMSON REUTERS
·
10 Jan

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

PR Newswire
·
10 Jan

Nektar Therapeutics (NKTR) Gets a Buy from Piper Sandler

TIPRANKS
·
10 Jan